Generic name: tarlatamab
Brand name: Imdelltra
Dosage form: intravenous powder for injection (dlle 1 mg; dlle 10 mg)
Drug class: Bispecific T-cell engagers (BiTE)

Medically reviewed by Drugs.com on Jul 12, 2024. Written by Cerner Multum.

What is tarlatamab?

Tarlatamab is used to treat non-small cell lung cancer in adults who are no longer responding to platinum-based chemotherapy.

Tarlatamab is used when the cancer has progressed or has spread to other parts of the body (metastatic).

Tarlatamab may also be used for purposes not listed in this medication guide.

Tarlatamab side effects

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Tarlatamab may cause serious side effects. Call your doctor at once if you have:

• low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath;

• signs of infection--fever, chills, sore throat, body aches, unusual tiredness, loss of appetite, bruising or bleeding; or

• symptoms of liver failure--diarrhea, loss of appetite, pain or swelling in your stomach, swelling in your legs, easy bleeding, drowsiness, confusion, or jaundice (yellowing of the skin or eyes).

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of tarlatamab may include:

• abnormal lab results;

• constipation, nausea;

• metallic taste in your mouth;

• muscle or bone pain;

• tiredness;

• fever; or

• loss of appetite.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Related/similar drugs

Warnings

Tell your medical caregivers if you have symptoms of a serious side effect, such as fever, chills, trouble breathing, vomiting, or severe tiredness.

Tarlatamab can also cause life-threatening nerve problems. Tell your caregivers or seek emergency medical attention if you have problems with speech, problems with thinking or memory, confusion, or a seizure.

Tarlatamab can increase your risk of serious bleeding. Stop using tarlatamab and call your doctor at once if you have severe stomach pain, bloody or tarry stools, coughing up blood, or any heavy or unusual bleeding.

Before taking this medicine

Tell your doctor if you have or have ever had:

• an allergic reaction to this medicine; or

• an active or chronic infection.

May harm an unborn baby. Use effective birth control while using tarlatamab and for at least 2 months after your last dose. Tell your doctor if you are pregnant or plan to become pregnant.

You may need to have a negative pregnancy test before starting this treatment.

Do not breastfeed while using this medicine, and for at least 2 months after your last dose.

How is tarlatamab given?

Tarlatamab is given as an infusion into a vein. A healthcare provider will give you this injection.

Tarlatamab is usually given once every 2 week in a 28-day treatment cycle. You will receive an injection only on certain days of this cycle.

tarlatamab must be given slowly over 60 minutes.

You may be given other medications to treat or prevent certain side effects.

Your blood will be tested before and during treatment with tarlatamab. You will need frequent blood tests to check your liver function.

Tarlatamab dosing information

Usual Adult Dose for Small Cell Lung Cancer:

Step-up Dosing Schedule to be administered as an intravenous infusion over one hour:
Cycle 1:
-Day 1: Step-up dose 1 mg IV
-Day 8: 10 mg IV
-Day 15: 10 mg IV
Cycle 2:
-Day 1 and 15: 10 mg IV
Cycles 3 and 4
-Day 1 and 15: 10 mg IV
Cycle 5 and subsequent infusions: 10 mg IV

Duration of therapy: After step-up dosing schedule, administration is every 2 weeks until disease progression or unacceptable toxicity.

Comments:
-Should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions

Use: Adult patients with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your tarlatamab injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while receiving tarlatamab?

Avoid driving or hazardous activity until you know how tarlatamab will affect you. Dizziness, drowsiness, confusion, tremors, or any other symptoms that impair consciousness can cause falls, accidents, or severe injuries.

What other drugs will affect tarlatamab?

Other drugs may affect tarlatamab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Tarlatamab Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for tarlatamab.

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright 1996-2025 Cerner Multum, Inc. Version: 1.01.